 (Philadelphia, PA) is celebrating what it describes as a significant milestone: The completion of its 150th Thorough QT clinical trial (TET).

“The TET study plays a crucial role in the development of a new pharmaceutical product," said John Blakeley, executive vice president of ERT, in a company press release. "We are very excited to have supported the industry to help improve the cardiac safety of new drugs coming to market."

With the advent of the ICH E14 Guidance in 2005, a TET has become a necessary part of the trials process for most drugs that require rigorous and robust electrocardiographic testing (ECG).